MHRAsafety guidance72% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Ganzhou Hemay Pharmaceutical Co., Ltd.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Gastroenterology · Ulcerative Colitis
- Sub-indication
- General
Related signal: Phase III Trial of Hemay005 in Chinese Patients with Ulcerative Colitis Initiated